HGH Fragment 176-191 by Meditech is a pharmaceutical-grade synthetic peptide corresponding to amino acid positions 176 through 191 of the human growth hormone (HGH) molecule, formulated as an injectable lyophilized preparation. This 16-amino acid C-terminal fragment has been isolated and investigated in peptide pharmacology research for its selective lipolytic properties, representing a structurally distinct and mechanistically targeted research compound relative to full-length somatropin preparations.
 
✔ Key Research Insights
Studied for its selective lipolytic activity, with documented enhancement of fat cell breakdown and concurrent inhibition of lipogenesis in research subjects, attributed to the C-terminal region of the HGH molecule responsible for growth hormone's fat metabolism signaling properties
Investigated for its mechanistic selectivity, with documented absence of IGF-1 stimulation and growth-promoting effects relative to full-length HGH in comparative peptide pharmacology research
Researched for its documented absence of effect on insulin sensitivity and glucose metabolism in research subject populations, a pharmacologically distinct characteristic relative to full somatropin preparations
Examined for its influence on lean mass preservation parameters during caloric deficit protocols in documented subject populations across peptide research literature
Documented for its effects on metabolic rate and caloric oxidation efficiency in comparative peptide pharmacology observations
Researched for its influence on recovery markers and tissue repair parameters in subject populations across documented peptide research protocols
Manufactured by Meditech to pharmaceutical-grade purity standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: HGH Fragment 176-191
Molecule: HGH C-Terminal Fragment (Amino Acids 176–191)
Concentration: 2 mg per vial
Form: Injectable lyophilized peptide
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
HGH Fragment 176-191 is a synthetic peptide analogue corresponding to the C-terminal region of the human growth hormone molecule, spanning amino acid positions 176 to 191. This specific region of the HGH sequence has been identified in peptide pharmacology research as the primary structural domain responsible for growth hormone's lipolytic signaling activity in adipose tissue. In research subjects, the fragment interacts with growth hormone receptors on fat cells, activating intracellular lipolytic pathways that stimulate the breakdown of stored triglycerides into free fatty acids — a process known as lipolysis — while concurrently inhibiting lipogenesis, the de novo synthesis and storage of new fat. Crucially, unlike full-length somatropin, HGH Fragment 176-191 does not interact with IGF-1 signaling pathways or growth hormone receptors responsible for anabolic growth promotion, resulting in the documented absence of growth-stimulating effects and insulin resistance associated with full HGH administration in comparative research. This mechanistic selectivity for lipolytic over growth-promoting receptor pathways represents the primary pharmacological research interest of this fragment relative to intact growth hormone preparations. Reconstitution with bacteriostatic water is standard protocol prior to subcutaneous administration in documented research settings.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
Synthetic C-terminal HGH fragment with a documented selective lipolytic mechanism distinct from full-length somatropin in comparative peptide pharmacology research
Documented absence of IGF-1 stimulation, growth-promoting effects, and insulin metabolism interference, representing a mechanistically targeted research profile relative to intact HGH preparations
Widely referenced in peptide pharmacology and metabolic research literature under the HGH Fragment 176-191 and AOD-9604 designations
Available in lyophilized vial format requiring reconstitution prior to subcutaneous administration per standard peptide research protocols